Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months

Trial Profile

Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2016

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms DISCOVERY123
  • Sponsors Terumo
  • Most Recent Events

    • 03 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
    • 03 Jul 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2016.
    • 11 May 2015 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top